These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10857996)

  • 1. CI-980 in advanced melanoma and hormone refractory prostate cancer.
    Ryan CW; Shulman KL; Richards JM; Kugler JW; Sosman JA; Ansari RH; Vokes EE; Vogelzang NJ
    Invest New Drugs; 2000 May; 18(2):187-91. PubMed ID: 10857996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group study.
    Whitehead RP; Unger JM; Flaherty LE; Eckardt JR; Taylor SA; Didolkar MS; Samlowski W; Sondak VK
    Invest New Drugs; 2001; 19(3):239-43. PubMed ID: 11561681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma.
    Kudelka AP; Hasenburg A; Verschraegen CF; Edwards CL; Meyers CA; Varma D; Freedman RS; Forman A; Conrad CA; Grove W; Grothey A; Kavanagh JJ
    Anticancer Drugs; 1998 Jun; 9(5):405-9. PubMed ID: 9660537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of intravenous CI-980 (NSC 370147) in patients with metastatic colorectal carcinoma. Model for prospective evaluation of neurotoxicity.
    Pazdur R; Meyers C; Diaz-Canton E; Abbruzzese JL; Patt Y; Grove W; Ajani J
    Am J Clin Oncol; 1997 Dec; 20(6):573-6. PubMed ID: 9391543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors.
    Sklarin NT; Lathia CD; Benson L; Grove WR; Thomas S; Roca J; Einzig AI; Wiernik PH
    Invest New Drugs; 1997; 15(3):235-46. PubMed ID: 9387046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of CI-980 (NSC 635370) in patients with previously treated advanced soft-tissue sarcomas.
    Patel SR; Burgess MA; Papadopolous NE; Sidhu G; Gray R; Plager C; Jenkins J; Benjamin RS
    Invest New Drugs; 1998; 16(1):87-92. PubMed ID: 9740549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of CI-980 in previously untreated extensive small cell lung cancer: an Ohio State University phase II research consortium study.
    Thomas JP; Moore T; Kraut EH; Balcerzak SP; Galloway S; Vandre DD;
    Cancer Invest; 2002; 20(2):192-8. PubMed ID: 11901539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.
    Kunschner LJ; Fine H; Hess K; Jaeckle K; Kyritsis AP; Yung WK
    Cancer Invest; 2002; 20(7-8):948-54. PubMed ID: 12449727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.
    Rowinsky EK; Long GS; Noe DA; Grochow LB; Bowling MK; Sartorius SE; Donehower RC
    Clin Cancer Res; 1997 Mar; 3(3):401-7. PubMed ID: 9815698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotoxicity of CI-980, a novel mitotic inhibitor.
    Meyers CA; Kudelka AP; Conrad CA; Gelke CK; Grove W; Pazdur R
    Clin Cancer Res; 1997 Mar; 3(3):419-22. PubMed ID: 9815700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study.
    Bernstein ML; Baruchel S; Devine S; Markoglou N; Wainer IW; Williams M; Blaney S; Moghrabi A; Winick N; Vietti T
    J Pediatr Hematol Oncol; 1999; 21(6):494-500. PubMed ID: 10598660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
    Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia.
    Gomez-Abuin G; Winquist E; Stadler WM; Pond G; Degendorfer P; Wright J; Moore MJ
    Invest New Drugs; 2007 Apr; 25(2):181-5. PubMed ID: 16983508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of prolonged ambulatory infusion carboplatin with oral etoposide showing activity in prostate cancer.
    Olver IN; Stephenson J; Schulze D
    Cancer Chemother Pharmacol; 2000; 46(4):338-41. PubMed ID: 11052632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of pyrazine diazohydroxide in androgen-independent prostate cancer.
    Edelman MJ; Meyers FJ; Grennan T; Lauder J; Doroshow J
    Invest New Drugs; 1998; 16(2):179-82. PubMed ID: 9848583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of paclitaxel, estramustine phosphate and vinorelbine (Pacl-E-Vin) in advanced malignancies: triple tubulin targeting.
    Sewak S; Chachoua A; Hamilton A; Taneja S; Lee J; Utate M; Sorich J; Muggia FM
    Anticancer Drugs; 2003 Jan; 14(1):67-72. PubMed ID: 12544260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
    Kakolyris S; Kouroussis C; Souglakos J; Mavroudis D; Agelaki S; Kalbakis K; Androulakis N; Vardakis N; Vamvakas L; Georgoulias V
    Oncology; 2001; 61(4):265-70. PubMed ID: 11721172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
    Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
    Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
    Kuzel TM; Kies MS; Wu N; Hsieh YC; Rademaker AW
    Cancer Invest; 2002; 20(5-6):634-43. PubMed ID: 12197218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Canil CM; Moore MJ; Winquist E; Baetz T; Pollak M; Chi KN; Berry S; Ernst DS; Douglas L; Brundage M; Fisher B; McKenna A; Seymour L
    J Clin Oncol; 2005 Jan; 23(3):455-60. PubMed ID: 15659491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.